| Code | CSB-RA011662MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Depemokimab, targeting interleukin-5 (IL-5), a key cytokine in eosinophil biology. IL-5 plays a central role in the differentiation, maturation, activation, and survival of eosinophils, a type of white blood cell involved in allergic and inflammatory responses. Elevated IL-5 levels and eosinophilia are associated with several respiratory conditions including severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and hypereosinophilic syndrome. By binding to IL-5, this antibody prevents the cytokine from interacting with its receptor on eosinophil surfaces, thereby inhibiting eosinophil-mediated inflammatory processes.
Depemokimab is an investigational long-acting monoclonal antibody developed for the treatment of eosinophilic disorders and has shown promise in clinical trials for severe asthma management. This biosimilar antibody serves as a valuable research tool for investigating IL-5-mediated pathways, eosinophil biology, and the pathophysiology of eosinophilic diseases. It enables researchers to explore therapeutic mechanisms and conduct preclinical studies in immunology and respiratory disease models.
There are currently no reviews for this product.